Cargando…
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line len...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380904/ https://www.ncbi.nlm.nih.gov/pubmed/28304402 http://dx.doi.org/10.1038/bcj.2017.20 |
_version_ | 1782519833959596032 |
---|---|
author | Leleu, X Kyriakou, C Vande Broek, I Murphy, P Bacon, P Lewis, P Gilet, H Arnould, B Petrucci, M T |
author_facet | Leleu, X Kyriakou, C Vande Broek, I Murphy, P Bacon, P Lewis, P Gilet, H Arnould, B Petrucci, M T |
author_sort | Leleu, X |
collection | PubMed |
description | Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in <6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort. |
format | Online Article Text |
id | pubmed-5380904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53809042017-05-01 Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment Leleu, X Kyriakou, C Vande Broek, I Murphy, P Bacon, P Lewis, P Gilet, H Arnould, B Petrucci, M T Blood Cancer J Original Article Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in <6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort. Nature Publishing Group 2017-03 2017-03-17 /pmc/articles/PMC5380904/ /pubmed/28304402 http://dx.doi.org/10.1038/bcj.2017.20 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Leleu, X Kyriakou, C Vande Broek, I Murphy, P Bacon, P Lewis, P Gilet, H Arnould, B Petrucci, M T Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title_full | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title_fullStr | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title_full_unstemmed | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title_short | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
title_sort | prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380904/ https://www.ncbi.nlm.nih.gov/pubmed/28304402 http://dx.doi.org/10.1038/bcj.2017.20 |
work_keys_str_mv | AT leleux prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT kyriakouc prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT vandebroeki prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT murphyp prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT baconp prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT lewisp prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT gileth prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT arnouldb prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment AT petruccimt prospectivelongitudinalstudyonqualityoflifeinrelapsedrefractorymultiplemyelomapatientsreceivingsecondorthirdlinelenalidomideorbortezomibtreatment |